Alvimopan, a perpherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
You are viewing the full content

[Surg Endosc (2006) 20: 64–70, DOI: 10.1007/s00464-005-0104-y]

On page 65, in column 1 of the “Patients and methods” section, the wrong study number was published. The first sentence under the heading “Study design and treatments” should read:

This was a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (Study 14CL308) designed to evaluate the efficacy and safety of 6 and 12 mg alvimopan for the management of POI in patients undergoing BR or TAH.

The online version of the original article can be found at http://dx.doi.org/10.1007/s00464-005-0104-y